Moderna's Melanoma Breakthrough Has Wall Street Drawing Wildly Different Conclusions

Moderna's stock trades 45% above consensus price target after landmark cancer vaccine data, but analyst targets range from $77 to $170 amid execution doubts.

The gap between what analysts think Moderna is worth and where the stock actually trades has rarely been wider. With the share price hovering near €133.96, the consensus price target of $74.31 sits roughly 45 percent below the market — a disconnect that captures just how fractured the sell-side has become over the company's pivot into oncology.

That pivot began in earnest on August 19, when Moderna and partner Merck announced their phase 3 trial for the personalized mRNA cancer vaccine intismeran autogene had hit both primary and secondary endpoints. The study, which enrolled more than 1,100 high-risk melanoma patients with stage IIB to IV disease, showed the combination with Keytruda significantly reduced the risk of recurrence compared with Keytruda alone. It marked the first positive phase 3 readout for an mRNA-based cancer therapy in history, and the shares responded with a single-day surge of roughly 177 percent.

A Target Range That Spans $93

Since then, the analyst community has sorted itself into camps that are difficult to reconcile. Bank of America upgraded the stock from Sell to Hold and lifted its price objective from $40 to $170, calling the melanoma data a "turning point" in Moderna's diversification away from infectious diseases. Barclays sees $125, RBC Capital $130, and Loop Capital $135, while UBS's Michael Yee described the update as an "initial door opener" for the oncology franchise and raised his target to $150. William Blair went further, upgrading the shares to Outperform.

At the other end of the spectrum sits JPMorgan, which has held firm with an Underweight rating and a $77 target. The bank's skepticism is rooted less in the science than in the commercial execution: no regulatory filing has been submitted yet, let alone approved, and the path from a positive phase 3 result to a marketed product can stretch over years. Wolfe Research, meanwhile, lifted its stance to Peer Perform and models peak sales of $9.2 billion for intismeran — a figure that towers over Leerink's projection of just $2 to $3 billion in 2032 revenue, while Merck's own internal estimates point to $6 billion by 2035.

The sheer breadth of those assumptions — a $93 spread between the lowest and highest targets — explains why the consensus remains stuck at Hold even after the summer rally. Many houses simply have not yet folded the full implications of the melanoma win into their models.

Institutions Keep Buying Even as Insiders Cash Out

The analyst discord has not deterred institutional money. Northwestern Mutual Wealth Management added 14,469 shares during the second quarter, worth roughly $1.01 million, while Vise Technologies increased its position by 5,447 shares at a cost of about $381,000. Institutions now control 75.33 percent of Moderna's outstanding shares — a sign that large investors see further upside despite the already dramatic run.

Insiders, however, have been taking profits. CEO Stéphane Bancel sold shares worth approximately $28.7 million, and president Stephen Hoge disposed of around $4.6 million net in July. Both transactions occurred under pre-existing 10b5-1 trading plans, so they carry no signal value on their own — but they do underscore that those closest to the company are willing to realize gains at current levels.

The Balance Sheet Clock Is Ticking

The fundamental question hanging over the stock is not whether intismeran works — that now appears settled — but whether Moderna can convert the clinical win into a commercially viable oncology platform before its cash runway runs out. The company posted a GAAP net loss of $0.8 billion in the second quarter on revenue of just $145 million, and it expects to end the year with between $4.7 billion and $5.2 billion in liquid assets. That figure effectively determines how much time the company has to turn the melanoma result into revenue.

There have also been setbacks that temper the enthusiasm. The norovirus vaccine candidate mRNA-1403 failed to meet the statistical criteria for early success at an interim phase 3 analysis in July — a reminder that not every pipeline program is advancing smoothly. And on the competitive front, Bancel has warned that China is closing the gap in mRNA technology, backed by state funding programs, with Chinese biotech firms already running more than a hundred of their own cancer vaccine programs. Moderna is responding by expanding its US manufacturing capacity, but the warning highlights that the technological edge underpinning the current valuation is not permanently secured.

A Diversification Hedge Emerges

One development that strengthens the bull case is the FDA approval of Moderna's influenza vaccine mFLUSIVA in early August, cleared for adults aged 50 and older and expected to be available in time for the 2026/2027 respiratory season. A portfolio spanning both oncology and infectious diseases would reduce the company's dependence on any single regulatory decision — though for now, the melanoma program remains the primary driver of the share price.

The stock sits roughly 10 percent below its 52-week high of €149.62, reached just days ago, and trades at more than six times its year-low of €19.36. That extraordinary range — from the depths of the post-pandemic revenue collapse to a historic clinical breakthrough — captures how completely the risk-reward profile has shifted. The next concrete milestone is the planned regulatory submission for intismeran in the coming months. Until that filing lands, the debate between those who see a transformative oncology franchise and those who see an overextended valuation will likely continue unresolved.